Evidence map›Paper›PMID 40805244›Full record

ReviewCancers2025

Breaking Barriers with Sound: The Implementation of Histotripsy in Cancer.

Ashutosh P Raman, Parker L Kotlarz, Alexis E Giff, Katherine A Goundry, Paul Laeseke, Erica M Knavel Koepsel, Mosa Alhamami, Dania Daye

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ashutosh P RamanHarvard Medical School, Boston, MA 02115, USA.
Parker L KotlarzHarvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-3667-8908
Alexis E GiffHarvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-9301-9928
Katherine A GoundryHarvard Medical School, Boston, MA 02115, USA.
Paul LaesekeDepartment of Radiology, University of Wisconsin, Madison, WI 53705, USA.
Erica M Knavel KoepselDepartment of Radiology, University of Wisconsin, Madison, WI 53705, USA.
Mosa AlhamamiDepartment of Radiology, University of Wisconsin, Madison, WI 53705, USA.ORCID 0009-0009-2459-5591
Dania DayeHarvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-2230-7199

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histotripsy is a novel, noninvasive, non-thermal technology invented in 2004 for the precise destruction of biologic tissue. It offers a powerful alternative to more conventional thermal or surgical interventions. Using short-pulse, low-duty cycle ultrasonic waves, histotripsy creates cavitation bubble clouds that selectively and precisely destroy targeted tissue in a predefined volume while sparing critical structures like bile ducts, ureters, and blood vessels. Such precision is of value when treating tumors near vital structures. The FDA has cleared histotripsy for the treatment of all liver tumors. Major medical centers are currently spearheading clinical trials, and some institutions have already integrated the technology into patient care. Histotripsy is now being studied for a host of other cancers, including primary kidney and pancreatic tumors. Preclinical murine and porcine models have already revealed promising outcomes. One of histotripsy's primary advantages is its non-thermal mechanical actuation. This feature allows it to circumvent the limitations of heat-based techniques, including the heat sink effect and unpredictable treatment margins near sensitive tissues. In addition to its non-invasive ablative capacities, it is being preliminarily explored for its potential to induce immunomodulation and promote abscopal inhibition of distant, untreated tumors through CD8+ T cell responses. Thus, it may provide a multilayered therapeutic effect in the treatment of cancer. Histotripsy has the potential to improve precision and outcomes across a multitude of specialties, from oncology to cardiovascular medicine. Continued trials are crucial to further expand its applications and validate its long-term efficacy. Due to the speed of recent developments, the goal of this review is to provide a comprehensive and updated overview of histotripsy. It will explore its physics-based mechanisms, differentiating it from similar technologies, discuss its clinical applications, and examine its advantages, limitations, and future.

Indexed as

ablationcavitationhepatocellular carcinomahistotripsyimmunomodulationinterventional radiologymetastatic colorectal carcinomanon-invasivereal-time feedbackultrasound

Identifiers

PMID40805244
PMCPMC12346746

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.